About Us

Comprehensive Trials Testing Management.

Precision Pathology. Specialised Oncology Services.

Our Mission:

We strive to be a global leader in transforming cancer through pioneering research, innovative clinical trial testing and the delivery of tailored clinical trial support and testing for accurate outcomes.

Our Vision:

Our vision is to empower Peter Mac researchers with state-of-the-art oncology testing and clinical trial support services whilst strategically building our market reach across Australia and the APAC region. This synergistic approach will fuel an expansion of our comprehensive services, specialist expertise, and cutting-edge capabilities, building toward Australia's leading cancer testing and clinical trial service.

Our Values:

At nexomics, our core values of excellence, innovation, integrity and collaboration are the bedrock of our commitment to accurate, timely and quality pathology testing, and clinical trial support services.

This commitment fuels our vision to be Australia's leading comprehensive cancer testing service by fostering a collaborative and inclusive environment driving the development of enhanced end-to-end pathology solutions through our integrated dedicated team of clinical trial specialists.

Excellence: Striving for excellence in our delivery of clinical trial testing to support clinical research.
Innovation: Driving progress through adoption of cutting-edge technologies.
Integrity: Upholding the highest ethical and quality standards in all our endeavours.
Collaboration: Fostering a culture of teamwork, both internally and with our external academic and commercial partners.

Our Story

2016

Leading the Way: Peter Mac Pathology Launches nexomics for Clinical Trials Testing Management.

Recognising the need for dedicated support for high-quality clinical trials, nexomics (a business unit) was established to coordinate and execute these complex requests whilst leveraging the specialised oncology pathology services delivered by the Department of Pathology (Pathology Laboratory) at Peter Mac.

2018

Assembly of clinical trial and pathology specialists

In 2018, the team underwent a gradual expansion in the scientific, operational and business development areas, further emphasising the value of nexomics to both internal and commercial partners and the need to build on our service. This began a period of expansion of the test menu and trial services, leading to substantial growth through operational and business development of the nexomics clinical trials unit.

‍

2019

Leading the Way in Comprehensive Genomic Profiling

Under the stewardship of Professor Stephen Fox, Peter Mac Pathology and nexomics became the first lab in Australia to offer validated Comprehensive Genomic Profiling (CGP). This breakthrough companion diagnostic capability empowers oncologists with critical genomic insights that enable personalised treatment strategies for cancer patients, spearheading the field of precision oncology testing across the APAC region. Nexomics and Peter Mac Pathology continued to enhance CGP by participation in national and international testing programs including (MoST, ASPIRATION, CaSP, and in more recently, PrOSPeCT). Our molecular test offering is expanded to include additional genomic biomarkers: tumour mutational burden (TMB) and microsatellite instability (MSI) and other genomic signatures that support the diagnosis of difficult to diagnose tumours.

2022

Using the most advanced technologies our offering in clinical trial testing now includes oncology specific services; anatomical pathology (IHC, ISH), immunology (flow cytometry, ELISA), molecular pathology (FISH, qPCR, ddPCR and NGS) and molecular haematology specialised testing, providing researchers and clinicians with the tools they need to drive discoveries, diagnostic and drug development and improve overall patient care.

2024

Expansion of Specialised Molecular Oncology Services

In 2024, oncology clinical trials represented 45% of the global clinical trial market nexomics increased offering, coupled with our expanded scientific and technical capabilities, introduced new dynamic processes and systems to better manage the increased demand for centralised clinical trial testing for oncology trials in Australia. Working closely with the Deaprtment of Pathology at Peter Mac and the Collaborative Centre of Genomic Cancer Medicine (a joint venture of the University of Melbourne and the Peter MacCallum Cancer Centre), has allowed nexomics to expand on its comprehensive suite of specialised molecular oncology testing services to include a suite of novel molecular haematology tests and an expanded liquid biopsy test offering to include cfTSO500 alongside the OPA ctDNA and comprehensive genomic profiling offering (TSO500 and TSO500 HRD).

‍

2025

Continual Commitment to Innovation & Excellence

Over the past decade, nexomics has grown into an operational team of medical lAt nexomics, our dedication to excellence, combined with our passion for enabling future cancer diagnostics and medicines drives us to deliver exceptional results for our clients and contribute to the fight against cancer.

Over the past decade, nexomics has grown into an operational team of medical laboratory professionals, clinical trial coordinators, operational managers, researchers and experts in diagnostic pathology, immunology and molecular pathology.

We are proud to have cultivated a collaborative environment that brings together individuals from public health and industry sectors who are all dedicated to facilitating, coordinating and executing high-quality diagnostic pathology and clinical trials services at Peter MacCallum Cancer Centre.

Our commitment to exploring new technology platforms that optimise workflows and investing in our team's professional development ensures we remain at the forefront of clinical trials testing and compliance.

Nexomics is enhancing its capabilities by introducing TruSight Oncology 500 HRD (TSO500 HRD) testing, which includes Homologous Recombination Deficiency (HRD) analysis, alongside advancements in spectral flow cytometry, an expanding immunohistochemistry (IHC) repertoire as well as active participation in tumour board discussions.

Next up